1129P Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up

Orloff, M., Watkins, C., Carvajal, R. D., Shoushtari, A. N., Sacco, J. J., Schlaak, M., Gama, J., & Butler, M. O. (2023). 1129P Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up. Annals of Oncology, 34, S678. https://doi.org/10.1016/j.annonc.2023.09.2263
Authors:
M. Orloff
C. Watkins
Richard D. Carvajal
Alexander N. Shoushtari
Joseph J. Sacco
Max Schlaak
Juliana Almeida Nogueira da Gama
Marcus O. Butler
Affiliated Authors:
Richard D. Carvajal
Columbia Affiliation:
Subjects:
Immunobiology of Dendritic Cells (OpenAlex Topic)
Ocular Cancer Research and Treatment (OpenAlex Topic)
Chimeric Antigen Receptor T Cell Therapy (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1016/j.annonc.2023.09.2263
DOI:
10.1016/j.annonc.2023.09.2263
Journal:
Annals of Oncology
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: